FGFR4-IN-14

• UNSPSC Description:

  FGFR4-IN-14 (Compound 27i) is a FGFR4 inhibitor (IC50: 2.4 nM. FGFR4-IN-14 inhibits the proliferation of V550L and N535K mutant strains, with IC50s of 21 nM, 2.5 nM, 171 nM against huh7, BaF3/ETV6-FGFR4-V550L and BaF3/ETV6-FGFR4-N535K cells respectively. FGFR4-IN-14 has potent antitumor efficacy in the Huh7 xenograft model. FGFR4-IN-14 can be used for research of hepatocellular carcinoma (HCC)[1].

• Target Antigen:

  FGFR

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/fgfr4-in-14.html

• Solubility:

  10 mM in DMSO

• Smiles:

  C=CC(NC1=CC2=C(C=C1C3=NNC4=C3C=C(O[C@@H](C5=C(Cl)C=NC=C5Cl)C)C=C4)CCN(C)C2)=O

• Molecular Weight:

  522.43

• References & Citations:

  [1]Yang Y, et al. Design, synthesis and biological evaluation of indazole derivatives as selective covalent inhibitors of FGFR4 in wild-type and gatekeeper mutants. Eur J Med Chem. 2023 Oct 5;258:115628.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  3027827-02-4